Chemotherapy in commercial VBC: 5 opportunities (and 1 area to avoid)

Complimentary resource for health care leaders

In our recent analysis of a national commercial data set of professional claims, chemotherapy was the fifth highest-cost sub-service line—even without taking drug costs into account—and cancer spending is projected to increase by 34% between 2015 and 2030.

There is definite savings opportunity for chemotherapy under value-based care, but the opportunity is difficult to address because cancer is a personal and scary issue. Our analysis outlines three proven strategies, two emerging opportunities to consider, and one area to avoid.

Please complete the form to the right to download an excerpt of our work..

About Advisory Board

For over 40 years, Advisory Board has researched health care's top challenges to provide leaders with the strategic guidance needed to push the industry forward. Our team of nearly 200 experts serves over 4,500 organizations that include hospitals, health systems, post-acute care providers, physician groups, life sciences firms, digital health companies, and health plans and more. Learn more at advisory.com/about-us.

Download now

First Name*

Last Name*

Email*

Please enter a valid email address

Company*

Job Title*

Management Level*

City*

State or Province*

Country*

I’d like more information on how Advisory Board supports value-based care initiatives.

Advisory Board uses the information you provide to contact you about our related content and services. You may unsubscribe from these communications at any time. For more information, check out our privacy policy.